4
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Biotech’s cell therapy boom keeps expanding beyond cancer: CREATE Medicines just raised $122 million to advance its in vivo CAR-T for autoimmune disease into the clinic.
Meanwhile, the Trump administration is searching for a new FDA commissioner, setting up a politically fraught fight over the agency’s future direction.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
